BQ Prime’s special research section collates quality and in-depth equity and economy research reports from across India’s top brokerages, asset managers and research agencies. These reports offer BQ Prime’s subscribers an opportunity to expand their understanding of companies, sectors and the economy.
Prabhudas Lilladher Report
We expect pharmaceuticals companies under our coverage to report flat Ebitda growth YoY (up 13% QoQ) mainly led by-
high base,
normalised expenses and
comparatively higher inflationary cost of goods sold on YoY.
However, we see strong sequential growth aided by niche launches in U.S., steady domestic formulation business and easing of overheads like freight, commodity prices.
The benefit of Indian rupee depreciation versus U.S. dollar (up 7% YoY and 3% QoQ) will also aid profitability. On the flip side, profitability will be negatively impacted by emerging market currency volatility.
We expect hospital companies under our coverage to anticipate 4% YoY growth (12% QoQ) in post India accounting standard Ebitda. As Q2 being a seasonally strong quarter, we expect occupancy improvement across our coverage universe. We anticipate average revenue per occupied bed to continue to remain healthy aided by improving case and payor mix.
Click on the attachment to read the full report:
DISCLAIMER
This report is authored by an external party. BQ Prime does not vouch for the accuracy of its contents nor is responsible for them in any way. The contents of this section do not constitute investment advice. For that you must always consult an expert based on your individual needs. The views expressed in the report are that of the author entity and do not represent the views of BQ Prime.
Users have no license to copy, modify, or distribute the content without permission of the Original Owner.
As a Subscriber you get
Stories
RECOMMENDED FOR YOU
POPULAR